Home › Acute Myeloid Leukemia › Maryland
Acute Myeloid Leukemia clinical trials in Maryland
31 studies for Acute Myeloid Leukemia are looking for participants at sites in Maryland.
Cities in Maryland
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2Healthy volunteers welcome
Ages 12 to 120 · All sexes · Updated Nov 10, 2026 · NCT05436418Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Baltimore MD-UMGCCC, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07223814Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- and 10 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06852222Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06484062Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 3 to 35 · All sexes · Updated Nov 3, 2026 · NCT02390752MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 2, 2026 · NCT06904066Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Maryland Medical Center (UMMC), Baltimore
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 30, 2026 · NCT05429632Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
1 Day – 120 Years · All sexes · Updated Oct 16, 2026 · NCT05350748Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Oct 16, 2026 · NCT05588154Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
1 Month – 120 Years · All sexes · Updated Oct 16, 2026 · NCT07019155A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- The Center for Cancer and Blood Disorders, Bethesda
RecruitingObservational study
Ages 0 and older · All sexes · Updated Oct 9, 2026 · NCT07154823Longitudinal Studies of Patient With FPDMM
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
1 Day – 100 Years · All sexes · Updated Oct 9, 2026 · NCT03854318Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06398457A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Johns Hopkins University, Baltimore
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 18, 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- and 1 more
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- John Hopkins School of Medicine, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06824168Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Baltimore MD-UMGCCC, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Maryland/Greenebaum Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 25, 2026 · NCT05886049Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
- Tania Jain, MD, Baltimore
RecruitingPhase 1
6 Months – 80 Years · All sexes · Updated Aug 14, 2026 · NCT02203903A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT04050280Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04068597A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Johns Hopkins School of Medicine, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Johns Hopkins University, Baltimore
RecruitingHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Jul 25, 2025 · NCT05237258From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.